4-Methylthiazole triggers apoptosis and mitochondrial disruption in HL-60 cells
Neslihan Meriç1, Ezgi Kar2, Fatih Kar3
1Faculty of Engineering and Natural Sciences, Department of Molecular Biology and Genetics, Kütahya Health Sciences University, Kütahya, Turkey. neslihan.meric@ksbu.edu.tr.
Background:
Thiazole derivatives are gaining prominence in cancer research due to their potent anti-cancer effects and multifaceted biological activities. In leukemia research, these compounds are particularly studied for their ability to induce apoptosis, disrupt mitochondrial membrane potential (MMP), and modulate cell signaling pathways.
Methods And Results:
This study investigates the efficacy of 4-Methylthiazole in inducing apoptosis in HL-60 leukemia cells. Apoptosis was quantified via flow cytometry using FITC Annexin V and propidium iodide staining. Mitochondrial disruption was evaluated through alterations in mitochondrial membrane potential (MMP) as measured by the JC-1 assay. The compound significantly disrupted MMP, activated Caspase-3, and induced the release of Cytochrome C, all of which are critical markers of apoptosis (****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05). Additionally, treatment with 4-Methylthiazole markedly reduced CD45 and CD123 surface markers, indicating significant phenotypic alterations in leukemia cells (****p < 0.0001). High-dose treatment with 4-Methylthiazole significantly increased ROS levels, suggesting elevated oxidative stress and the presence of intracellular free radicals, contributing to its cytotoxic effects (*p < 0.05). A significant rise in TNF-α levels was observed post-treatment, indicating a pro-inflammatory response that may further inhibit leukemia cell viability. While IL-6 levels remained unchanged, a dose-dependent decrease in IL-10 levels was noted, suggesting a reduction in immunosuppressive conditions within the tumor microenvironment (*p < 0.05).
Conclusions:
Overall, 4-Methylthiazole targets leukemia cells through multiple apoptotic mechanisms and modifies the immune landscape of the tumor microenvironment, enhancing its therapeutic potential. This study highlights the need for further clinical investigation to fully exploit the potential of thiazole derivatives in leukemia treatment.
Insights
4-Methylthiazole induces apoptosis in leukemia cells by disrupting mitochondrial membrane potential and activating key cell death markers. This thiazole derivative also alters leukemia cell surface markers and modulates the tumor microenvironment, showing therapeutic promise.
Area of Science:
- Biochemistry
- Molecular Biology
- Immunology
Background:
- Thiazole derivatives exhibit potent anti-cancer properties, making them significant in cancer research.
- These compounds are particularly investigated for their role in inducing apoptosis, disrupting mitochondrial membrane potential (MMP), and modulating cell signaling pathways in leukemia.
Purpose of the Study:
- To investigate the efficacy of 4-Methylthiazole in inducing apoptosis in HL-60 leukemia cells.
- To evaluate the effects of 4-Methylthiazole on mitochondrial membrane potential, cell surface markers, oxidative stress, and cytokine profiles in leukemia cells.
Main Methods:
- Apoptosis quantification using flow cytometry (FITC Annexin V and propidium iodide staining).
- Mitochondrial membrane potential (MMP) assessment via JC-1 assay.
- Analysis of Caspase-3 activation, Cytochrome C release, surface markers (CD45, CD123), reactive oxygen species (ROS) levels, and cytokine profiles (TNF-α, IL-6, IL-10).
Main Results:
- 4-Methylthiazole significantly disrupted MMP, activated Caspase-3, and induced Cytochrome C release, indicating apoptosis induction.
- The compound markedly reduced CD45 and CD123 surface markers on leukemia cells.
- High-dose 4-Methylthiazole increased ROS levels and TNF-α, while decreasing IL-10, suggesting oxidative stress and immune modulation.
Conclusions:
- 4-Methylthiazole effectively targets leukemia cells via multiple apoptotic pathways.
- The compound modifies the tumor immune microenvironment, enhancing its therapeutic potential.
- Further clinical investigation of thiazole derivatives for leukemia treatment is warranted.
